Influenza News and Research

Latest Influenza News and Research

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector boost regimen that was developed to protect against diverse subtypes of HIV-1 prevalent in North America, Europe, Africa, and South America.

29 Sep 2010

Outbreak of whooping cough mirrors challenges in developing world, global health official says

The outbreak of whooping cough in Texas, California, and other states this year underscores the critical importance of widespread vaccination coverage, both locally as well as around the world, said a leading global health official attending conferences on world affairs and immunization in Fort Worth this week.

29 Sep 2010

CAP cells produce high virus titers upon influenza strain infection

CEVEC Pharmaceuticals, the developer of an extremely potent protein expression system based on human CAP cells, announced today that CAP cells produce high virus titers upon infection with influenza strains. The virus titers are as good as or even higher than with MDCK and Vero cells, host cells currently used for influenza vaccine production.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

Akonni Biosystems, a molecular diagnostics company that develops, manufactures, and plans to market sophisticated genetic testing devices for complex infectious and human diseases, today announced receipt of a nearly $3 million Challenge Grant from the National Institutes of Health (NIH), a new program made possible under the American Recovery and Reinvestment Act (ARRA).

29 Sep 2010

Study finds that 90% of EDs nationwide also offer preventive-care services

People go to emergency departments when they've broken a leg, been stabbed or otherwise need urgent care. But a new study from the Stanford University School of Medicine finds that 90 percent of EDs nationwide also offer preventive-care services.

28 Sep 2010

Portable humidifiers may reduce airborne influenza virus: Study

A new scientific study published in the open access, peer-reviewed journal Environmental Health indicates that the use of portable humidifiers in the home may reduce the survival of airborne influenza virus by controlling humidity indoors.

28 Sep 2010

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company's Mimopath technology in oral vaccines to prevent and treat severe diarrhea.

28 Sep 2010

WA teenage death related to swine flu

Teenager Andrew Allan died hours after being sent home from Northam Hospital, Western Australia (WA) with some Paracetamol by a nurse on the 17th September. He was ill with fever and vomiting but was not assessed by a doctor. Health officials now believe his illness was due to swine flu and are urging people to get vaccinated. Nine people have died from swine flu in WA this year.

26 Sep 2010

3M announces series of educational events to combat healthcare-associated infections

As a company on a mission to help hospitals fight healthcare-associated infections (HAIs), 3M Infection Prevention today announced a series of educational events taking place the week of September 27.

24 Sep 2010

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin therapy alone.

24 Sep 2010

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

Cerus Corporation announced today that it has received an additional $1.4 million from the U.S. Department of Defense to support advanced development of the company's pathogen inactivation technology for red blood cells. The INTERCEPT red blood cell system is a pathogen inactivation product Cerus is developing to prevent the transmission of infectious diseases through red blood cell transfusions.

24 Sep 2010

Swine flu making a come back

A second elderly man succumbed to the swine flu virus as the Northern Territory experiences an upsurge in infection rates from the virus. Both men had serious health problems that raised their risk of dying with the disease.

24 Sep 2010

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

NanoViricides, Inc., announced today that it had reached an agreement with Seaside 88, LP a Florida limited partnership, for the exercise of Seaside's option to purchase an additional $2.5M of the Company's Series B Convertible Preferred Stock.

23 Sep 2010

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.

23 Sep 2010

FDA approves Gilenya capsules for reducing MS relapses

The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).

22 Sep 2010

Nationwide Health Information Network tool to convey public health information

One hundred and sixty-six years after Samuel Morse used dots and dashes to telegraph "What hath God wrought?" opening up a whole new world of communication, Indiana has become the first state in the nation to use a potentially equally revolutionary tool, the Nationwide Health Information Network, to convey public health information to the U.S. Centers for Disease Control and Prevention.

22 Sep 2010

MIDAS researchers continue to model how H1N1 may spread

As the United States prepares for the upcoming flu season, a group of researchers supported by the National Institutes of Health continues to model how H1N1 may spread.

22 Sep 2010

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Dutch biopharmaceutical company Crucell N.V. and the Aeras Global TB Vaccine Foundation today announced the start of a Phase II clinical trial in infants of the jointly developed tuberculosis (TB) vaccine candidate, AERAS-402/Crucell Ad35.

22 Sep 2010

Influenza News and Research

Latest Influenza News and Research

NIH trial selects Inovio's PENNVAX-G DNA vaccine candidate to evaluate HIV-1 prevalent

Outbreak of whooping cough mirrors challenges in developing world, global health official says

CAP cells produce high virus titers upon influenza strain infection

Early initiation of ART may prevent immune system damage in HIV patients: Study

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

NIH grants Akonni $3M for development of multi-drug resistant/extensively drug-resistant genotyping test

Study finds that 90% of EDs nationwide also offer preventive-care services

Portable humidifiers may reduce airborne influenza virus: Study

Mucosis collaborates with PATH to pursue use of Mimopath technology in diarrhea vaccines

WA teenage death related to swine flu

3M announces series of educational events to combat healthcare-associated infections

Phase 3 clinical study demonstrates efficacy of metformin therapy in type 2 diabetes

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

Swine flu making a come back

NanoViricides enters agreement with Seaside to purchase Series B Convertible Preferred Stock

BARDA awards Rapid Micro Biosystems $6.7M contract to develop rapid sterility testing platform for vaccines

FDA approves Gilenya capsules for reducing MS relapses

Nationwide Health Information Network tool to convey public health information

MIDAS researchers continue to model how H1N1 may spread

Aeras and Crucell commence Phase II study of TB vaccine candidate in infants

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Influenza News and Research

Latest Influenza News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in